Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression

Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression

Abstract Mesothelin (MSLN) is a prominent target antigen for CAR T cell therapy due to its extensive expression in various solid tumors, including pancreatic cancer. However, the therapeutic efficacy of MSLN-targeted CAR T cell therapy has been limited in clinical trials for pancreatic cancer, often...

Full description

Saved in:
Bibliographic Details
Main Authors: Mona Alhussein Aboalela, Mohamed Abdelmoneim, Shigeru Matsumura, Ibrahim Ragab Eissa, Itzel Bustos-Villalobos, Patricia Angela Sibal, Yu Orikono, Yuhei Takido, Yoshinori Naoe, Hideki Kasuya
Format: Article
Language:English
Published: Springer 2025-05-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Mesothelin
CAR T cell therapy
Oncolytic virus
Herpes virus
Pancreatic cancer
Syngeneic murine model
Online Access:https://doi.org/10.1007/s00262-025-04039-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04039-7

Similar Items